News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

All Stories

All
News
Press Releases
News

Scribe Therapeutics plans to test cholesterol-lowering epigenetic editing therapy

January 14, 2026

Endpoints

Read Now
News

CRISPR Slashes ‘Bad Cholesterol’ Levels by 95 Percent in Early Results

November 27, 2025

Singularity Hub

Read Now
News

Can AI take the guesswork out of CRISPR?

November 24, 2025

Drug Discovery News

Read Now
News

Can genetic medicine solve cardiovascular disease?

November 20, 2025

Longevity.Technology

Read Now
News

Scribe eyes clinic after CRISPR candidates lower lipids in animals

November 17, 2025

Fierce Biotech

Read Now
News

Epigenetic approach shows durable PCSK9 silencing in primates

October 15, 2025

BioWorld

Read Now
Press release

Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June

May 22, 2023

Read Now
Press release

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 19, 2023

Read Now
Press release

Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases

May 16, 2023

Read Now
Press release

Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 2, 2023

Read Now
Press release

Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

March 31, 2023

Read Now
Press release

Scribe Therapeutics to Participate in Four Upcoming Conferences

November 17, 2022

Read Now

Publications and presentations